Prijeđi na sadržaj

Latrepirdin

Izvor: Wikipedija
Latrepirdin
(IUPAC) ime
2,3,4,5-tetrahidro-2,8-dimetil-5-(2-(6-metil-3-piridil)etil)-1H-pirido(4,3-b)indol
Klinički podaci
Identifikatori
CAS broj 3613-73-8
ATC kod nije dodeljen
PubChem[1][2] 197033
ChemSpider[3] 170644
UNII OD9237K1Z6 
Hemijski podaci
Formula C21H25N3 
Mol. masa 319,443 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status ℞ Prescription only
Način primene Oralno

Latrepirdin (dimebolin, Dimebon) je antihistamin koji je u kliničkoj upotrebi u Rusiji od 1983.[4]

U toku su istraživanja njegove potencijalne primene kao neuroprotektivnog leka u borbi protiv Alchajmerove bolesti, kao i mogućnosti nootropne upotrebe.[5] Jedna od kliničkih studija u faze III za Alcheimerovu bolesti je utvrdila da on nije koristan. Tri druge studije su u toku.[6] Kliničko ispitivanje za Hantingtonovu bolest nije bilo uspešno.[7]

Farmakologija

[uredi | uredi kod]

Latrepirdin ima više mehanizama dejstva. On blokira dejstvo neurotoksičnih beta-amiloidnih proteina, inhibira L-tip kalcijumov kanal|kalcijumove kanale,[8] modulara dejstvo AMPA i NMDA glutamatnih receptora,[9] i može da ispolji neuroprotektivno dejstvo putem blokiranja bioloških meta koje učestvuju u permeabilnosti mitohondrijalnih pora,[10] za koje se smatra da doprinose ćelijskom izumiranju vezanom za neurodegenerativne bolesti i proces starenja.[11] On takođe blokira brojne druge receptore, uključujući α-adrenergičkai, 5-HT2C, 5-HT5A, i 5-HT6.[12] Latrepirdin nema antiholinergičko dejstvo.[13]

Reference

[uredi | uredi kod]
  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
  3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
  4. ↑ Matveeva IA (July 1983). „Action of dimebon on histamine receptors” (Russian). Farmakologiia i Toksikologiia 46 (4): 27–29. PMID 6225678.
  5. ↑ Shevtsova EF, Kireeva EG, Bachurin SO (2005). „Mitochondria as the target for neuroprotectors” (Russian). Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (9): 13–17. PMID 16250325.
  6. ↑ Novel Alzheimer's Drug Flops, MedPage Today, March 03, 2010
  7. ↑ Phase III Failure Leads Medivation and Pfizer to Ditch Dimebon for Huntington Disease
  8. ↑ Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO (November 2001). „Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels”. Bulletin of Experimental Biology and Medicine 132 (5): 1079–1083. DOI:10.1023/A:1017972709652. PMID 11865327.
  9. ↑ Grigorev VV, Dranyi OA, Bachurin SO (November 2003). „Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons”. Bull Exp Biol Med 136 (5): 474–477. DOI:10.1023/B:BEBM.0000017097.75818.14. PMID 14968164.
  10. ↑ Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (May 2003). „Mitochondria as a target for neurotoxins and neuroprotective agents”. Annals of the New York Academy of Sciences 993: 334–44; discussion 345–9. DOI:10.1111/j.1749-6632.2003.tb07541.x. PMID 12853325.[mrtav link]
  11. ↑ "Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy" (Press release). 2007-06-11.
  12. ↑ Wu J, Li Q, Bezprozvanny I (2008). „Evaluation of Dimebon in cellular model of Huntington's disease”. Molecular Neurodegeneration 3: 15. DOI:10.1186/1750-1326-3-15. PMC 2577671. PMID 18939977.
  13. ↑ Gankina EM, Porodenko NV, Kondratenko TI, Severin ES, Kaminka ME, Mashkovskiĭ MD (1993). „[The effect of antihistaminic preparations on the binding of labelled mepyramine, ketanserin and quinuclidinyl benzilate in the rat brain]” (Russian). Eksperimental'naia I Klinicheskaia Farmakologiia 56 (1): 22–4. PMID 8100727.

Povezano

[uredi | uredi kod]

Vanjske veze

[uredi | uredi kod]